Results

Total Results: 2,235 records

Showing results for "1".

1. Draft Research Plan: Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Falls and Fractures in Community-Dwelling Adults: Preventive Medication | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/draft-research-plan/vitamin-d-calcium-combined-supplementation-primary-prevention-falls-fractures-communitydwelling-adults
   January 12, 2023 - treatment not supplementation (e.g., calcitriol, alphacalcitriol, calcifediol); synthetic vitamin D … Study design KQ 1: RCTs, controlled clinical trials. … Timing KQ 1: Intervention duration of 1 month or longer. KQ 2: Any duration. … KQ 1: Intervention duration of less than 1 month. KQ 2: No exclusions. … Syst Rev . 2017;6(1):41.

2. Final Research Plan: Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Falls and Fractures in Community-Dwelling Adults: Preventive Medication | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/vitamin-d-calcium-combined-supplementation-primary-prevention-falls-fractures-communitydwelling-adults
   April 06, 2023 - treatment not supplementation (e.g., calcitriol or calcifediol); synthetic vitamin D analogs (i.e., … Study design KQ 1: RCTs, controlled clinical trials. … Timing KQ 1: Intervention duration of 1 month or longer. KQ 2: Any duration. … KQ 1: Intervention duration of less than 1 month. KQ 2: No exclusions. … Syst Rev . 2017;6(1):41.

3. peds20151711 1..8 (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/72ybMHDdg9WyFzrYMBF4ch
   August 01, 2015 - peds20151711 1..8 Screening for Speech and Language Delay and Disorders in Children Aged 5 Years or … The USPSTF identified 2 studies (1 fair-quality and 1 good-quality) on the potential harms of treatment … Pediatrics. 2011;128(1):14–19 9. Berkman ND, Wallace IF, Watson L, et al. … J Speech Hear Res. 1990; 33(1):70–83 15. Richman N, Stevenson J, Graham PJ. … Pediatrics. 2006;118(1):405–420 8 SIU

4. Evidence Summary: Falls Prevention in Community-Dwelling Older Adults: Interventions | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/falls-prevention-in-older-adults-interventions
   April 17, 2018 - trial of calcitriol showed a reduction in falls and people experiencing a fall; the remaining 5 trials … μg of 1-hydroxycholecalciferol daily 61 and 0.25 μg of calcitriol twice daily. 62 In 2 studies, the … Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. … J Geriatr Phys Ther . 2017;40(1):1-36. Return to Table of Contents Figure 1. … trial of calcitriol showed statistically significant reduction in falls (IRR, 0.63 [95% CI, 0.47-0.84

5. Final Research Plan: Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/vitamin-d-calcium-or-combined-supplementation-for-the-primary-prevention-of-fractures-in-adults-preventive-medication
   June 23, 2016 - Return to Recommendation Expand All Panel 1 The final Research … leads to improved fracture and fracture-related morbidity and mortality health outcomes (key question 1) … including daily or annual (vitamin D only) supplementation, as long as it is considered long term (≥1 … or metabolites not designed as supplements (e.g., calcitriol, alphacalcitriol, calcifediol) Synthetic … Intervention duration of ≥1 month KQ 2: Any duration KQ 1: Intervention duration of <1 month

6. Interventions to Prevent Falls in Older Adults: Updated Evidence Report and Systematic Review of the USPSTF (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/nMb54adBfgajp8dG87kPcw
   April 17, 2018 - trial of calcitriol showed a reduction in falls and people experiencing a fall; the remaining 5 trials … hydroxycholecalciferol,61 and calcitriol.62 The dosing schedules varied; the cholecalciferol trials … μg of 1-hydroxycholecalciferol daily61 and 0.25 μg of calcitriol twice daily.62 In 2 studies, the intervention … 000 IU) showed an increase in falls, people experiencing a fall, and injurious falls66; the trial of calcitriol … Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.

7. Archived: Evidence Summary: Hormone Therapy in Postmenopausal Women: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/menopausal-hormone-therapy-preventive-medication-december-2017
   December 12, 2017 - 1, 2016. … Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. … range for age CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 121) CEE (0.625 mg/d) + MPA (2.5 mg/d) + calcitriol … (0.25 μg twice daily) (n = 122) Calcitriol (0.25 μg twice daily) (n = 123) Placebo (n = 123 … −1) Endometrial cancer NA a −1 (−3 to 3) Lung cancer 1 (−4 to 8) 1 (−4 to 7)

8. Evidence Summary: Hormone Therapy in Postmenopausal Women: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/menopausal-hormone-therapy-preventive-medication
   December 12, 2017 - 1, 2016. … Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. … range for age CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 121) CEE (0.625 mg/d) + MPA (2.5 mg/d) + calcitriol … (0.25 μg twice daily) (n = 122) Calcitriol (0.25 μg twice daily) (n = 123) Placebo (n = 123 … −1) Endometrial cancer NA a −1 (−3 to 3) Lung cancer 1 (−4 to 8) 1 (−4 to 7)

9. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for the USPSTF (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/V7SNHdqvUyT7e2hQt5HbFp
   December 12, 2017 - normal range for age CEE (0.625 mg/d) + MPA (2.5 mg/d) (n = 121) CEE (0.625 mg/d) + MPA (2.5 mg/d) + calcitriol … (0.25 μg twice daily) (n = 122) Calcitriol (0.25 μg twice daily) (n = 123) Placebo (n = 123) Duration … NAa −1 (−3 to 3) Lung cancer 1 (−4 to 8) 1 (−4 to 7) Ovarian cancer No data 2 (−1 to 6)b Coronary … ,1 5 ,1 8 ,1 9 ,5 4 ,6 1 ,6 7 ,8 0 ;1 52 ev en ts in 19 37 1 w om en co nt rib ut e to … Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.

10. Final Recommendation Statement: Falls Prevention in Community-Dwelling Older Adults: Interventions | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/falls-prevention-in-older-adults-interventions
    April 17, 2018 - trial used 1-hydroxycholecalciferol (1 μg per day) and another used calcitriol (0.25 μg twice per day … J Trauma . 2001;50(1):116-9. 4. Alexander BH, Rivara FP, Wolf ME. … AHRQ Publication No. 17-05230-EF-1. … Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. … AHRQ Publication No. 17-05231-EF-1.

11. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/Rn7dRezgMx5syB-erQKoKt
    November 01, 2022 - Table 1. … normal range for age CEE (0.625 mg/d + MPA [2.5 mg/d]) (n = 121) CEE (0.625 mg/d + MPA [2.5 mg/d] plus calcitriol … [0.25 μg twice daily]) (n = 122) Calcitriol (0.25 μg twice daily) (n = 123) Placebo (n = 123) 3 y Fair … Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. … (1):1-9. doi:10.7326/0003-4819-138-1-200301070- 00005 89.

12. Evidence Summary: Hormone Therapy in Postmenopausal Persons: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary28/menopausal-hormone-therapy-preventive-medication
    November 01, 2022 - Benefits of Hormone Therapy Key Question 1. … Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. … Ann Intern Med . 2003;138:1-9. doi:10.7326/0003-4819-138-1-200301070-00005 89. … normal range for age CEE (0.625 mg/d + MPA [2.5 mg/d]) (n = 121) CEE (0.625 mg/d + MPA [2.5 mg/d] plus calcitriol … [0.25 μg twice daily]) (n = 122) Calcitriol (0.25 μg twice daily) (n = 123) Placebo (n = 123) 3 y

13. Recommendation: Falls Prevention in Community-Dwelling Older Adults: Interventions | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/falls-prevention-in-older-adults-interventions
    April 17, 2018 - trial used 1-hydroxycholecalciferol (1 μg per day) and another used calcitriol (0.25 μg twice per day … J Trauma . 2001;50(1):116-9. 4. Alexander BH, Rivara FP, Wolf ME. … AHRQ Publication No. 17-05230-EF-1. … Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. … AHRQ Publication No. 17-05231-EF-1.

14. News | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/news?page=1
    January 18, 2022 - Share to Facebook Share to X Share to WhatsApp Share to Email Print The following is information about the U.S. Preventive Services Task Force (USPSTF) for use by the media. The USPSTF is an independent panel of non-Federal experts that makes recommendat…

15. Procedure Manual Section 1. Overview of U.S. Preventive Services Task Force Structure and Processes | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/procedure-manual/procedure-manual-section-1
    December 01, 2013 - Procedure Manual Section 1. Overview of U.S. … Currently, members are invited to serve for a 4-year term, with a possible 1-year extension. … Table 1. … Figure 1. … Authorship credit should be based on: 1) substantial contributions to the conception, design, analysis

16. Announcements | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/news/announcements?page=1
    August 29, 2023 - First page « First Previous page ‹‹ Page 1

17. Update on Methods: Insufficient Evidence - Table 1 | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/update-on-methods-insufficient-evidence---table-1
    February 01, 2009 - Update on Methods: Insufficient Evidence - Table 1 Share to Facebook Share … X Share to WhatsApp Share to Email Print Table 1.

18. Individualizing Cancer Screening in Older Adults - Figure 1 | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/individualizing-cancer-screening-older-adults-figure-1
    October 01, 2012 - Individualizing Cancer Screening in Older Adults - Figure 1 Share to Facebook

19. Interventions to Prevent Falls in Community-Dwelling Older Adults: USPSTF Recommendation Statement (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/h-w99jVsodSL33kV2h2_qW
    April 17, 2018 - trial used 1-hydroxycholecalciferol (1 μg per day) and another used calcitriol (0.25 μg twice per day … REFERENCES 1. … J Trauma. 2001;50(1):116-119. 4. Alexander BH, Rivara FP, Wolf ME. … AHRQ publication 17-05230-EF-1. 9. … Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.

20. Screening for Visual Impairment in Children Ages 1–5 Years: Update for the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/r_MgZHrtyHRn7rZoCPS6MT
    February 01, 2011 - Key question 1. … RCT 1 retrospective cohort study 1 RCT 1 prospective cohort study 3 retrospective cohort … (1/113); media opacity: 1% (1/113) Pediatric ophthalmology clinic, United States, technician Cooper … ocular/ or vision screening/ 2. limit 1 to (“newborn infant (birth to 1 month)” or “infant (1–23 months … (1/113); media opacity: 1% (1/113) 0.65 (0.38–0.86) 0.98 (0.93–1.0) Cooper et al35 (1999) A, Fortune